抗生物質：世界の抗感染薬市場（第2巻）

当商品の販売は、2011年07月19日を持ちまして終了しました。

原文目次

Antibiotics: Global Anti-Infectives Markets Vol. II

Second volume in Theta' s three-part anti-infectives report series...

Theta' s in-depth analysis will provide you with:

• Global market analysis of a dozen antibiotic drug classes
• 2008 market size and growth projections
• Comprehensive overviews of major antibiotic drug classes
• Coverage of latest research and development activities
• Company briefs of leading and up-and-coming pharmaceutical firms

Major classes of antibiotic drugs included:

• Sulphonamides
• Penicillins
• Tetracyclines
• Cephalosporines
• Cephems
• Aminoglycosides
• Macrolides
• Glycopeptides
• Quinolones
• Carbapenems
• Oxazolidinones
• Streptogramins

An essential strategic resource, Theta' s Antibiotics: Global Anti-Infectives Markets Vol. II answer the following questions:

• What conditions currently require treatment with antibiotics?
• What types of antibiotics are available to treat these conditions?
• How do the various classes of antibiotics differ?
• What is the current market for antibiotic drugs by class?
• What are the competitive positions of the major players in the antibiotic market?
• What new antibiotics are currently in development?
• What are the key issues facing developers of antibiotic drugs now?

Table of Contents

1 Executive Summary

1.1 Scope and Objectives of the Report

1.2 Methodology

2 Introduction and Overview

2.1 Definition of Antibiotic Drugs

2.2 Classes of Antibiotic Drugs

2.3 Disease Conditions for Use

3 Issues and Trends in Antibiotics

3.1 Antibiotic Resistance

3.2 Emerging Disease Treatment Markets

3.3 Biodefense

4 Sulphonamides

4.1 Overview of Class

4.1.1 Mechanism of Action

4.1.2 Disease Conditions Treated

4.1.3 Adverse Event Profile

4.2 Global Market Analysis

4.2.1 Total World Market Size and Growth

4.2.2 U.S. Market Size and Growth

4.2.3 Western European Market Size and Growth

4.2.4 Japanese Market Size and Growth

4.2.5 Rest of World Market Size and Growth

4.3 Competitive Analysis

4.3.1 Leading Drugs

4.3.2 Leading Companies

5 Penicillins

5.1 Overview of Class

5.1.1 Mechanism of Action

5.1.2 Disease Conditions Treated

5.1.3 Adverse Event Profile

5.2 Global Market Analysis

5.2.1 Total World Market Size and Growth

5.2.2 U.S. Market Size and Growth

5.2.3 Western European Market Size and Growth

5.2.4 Japanese Market Size and Growth

5.2.5 Rest of World Market Size and Growth

5.3 Competitive Analysis

5.3.1 Leading Drugs

5.3.2 Leading Companies

6 Tetracyclines

6.1 Overview of Class

6.1.1 Mechanism of Action

6.1.2 Disease Conditions Treated

6.1.3 Adverse Event Profile

6.2 Global Market Analysis

6.2.1 Total World Market Size and Growth

6.2.2 U.S. Market Size and Growth

6.2.3 Western European Market Size and Growth

6.2.4 Japanese Market Size and Growth

6.2.5 Rest of World Market Size and Growth

6.3 Competitive Analysis

6.3.1 Leading Drugs

6.3.2 Leading Companies

7 Cephalosporins

7.1 Overview of Class

7.1.1 Mechanism of Action

7.1.2 Disease Conditions Treated

7.1.3 Adverse Event Profile

7.2 Global Market Analysis

7.2.1 Total World Market Size and Growth

7.2.2 U.S. Market Size and Growth

7.2.3 Western European Market Size and Growth

7.2.4 Japanese Market Size and Growth

7.2.5 Rest of World Market Size and Growth

7.3 Competitive Analysis

7.3.1 Leading Drugs

7.3.2 Leading Companies

8 Cephems

8.1 Overview of Class

8.1.1 Mechanism of Action

8.1.2 Disease Conditions Treated

8.1.3 Adverse Event Profile

8.2 Global Market Analysis

8.2.1 Total World Market Size and Growth

8.2.2 U.S. Market Size and Growth

8.2.3 Western European Market Size and Growth

8.2.4 Japanese Market Size and Growth

8.2.5 Rest of World Market Size and Growth

8.3 Competitive Analysis

8.3.1 Leading Drugs

8.3.2 Leading Companies

9 Aminoglycosides

9.1 Overview of Class

9.1.1 Mechanism of Action

9.1.2 Disease Conditions Treated

9.1.3 Adverse Event Profile

9.2 Global Market Analysis

9.2.1 Total World Market Size and Growth

9.2.2 U.S. Market Size and Growth

9.2.3 Western European Market Size and Growth

9.2.4 Japanese Market Size and Growth

9.2.5 Rest of World Market Size and Growth

9.3 Competitive Analysis

9.3.1 Leading Drugs

9.3.2 Leading Companies

10 Macrolides

10.1 Overview of Class

10.1.1 Mechanism of Action

10.1.2 Disease Conditions Treated

10.1.3 Adverse Event Profile

10.2 Global Market Analysis

10.2.1 Total World Market Size and Growth

10.2.2 U.S. Market Size and Growth

10.2.3 Western European Market Size and Growth

10.2.4 Japanese Market Size and Growth

10.2.5 Rest of World Market Size and Growth

10.3 Competitive Analysis

10.3.1 Leading Drugs

10.3.2 Leading Companies

11 Glycopeptides

11.1 Overview of Class

11.1.1 Mechanism of Action

11.1.2 Disease Conditions Treated

11.1.3 Adverse Event Profile

11.2 Global Market Analysis

11.2.1 Total World Market Size and Growth

11.2.2 U.S. Market Size and Growth

11.2.3 Western European Market Size and Growth

11.2.4 Japanese Market Size and Growth

11.2.5 Rest of World Market Size and Growth

11.3 Competitive Analysis

11.3.1 Leading Drugs

11.3.2 Leading Companies

12 Quinolones

12.1 Overview of Class

12.1.1 Mechanism of Action

12.1.2 Disease Conditions Treated

12.1.3 Adverse Event Profile

12.2 Global Market Analysis

12.2.1 Total World Market Size and Growth

12.2.2 U.S. Market Size and Growth

12.2.3 Western European Market Size and Growth

12.2.4 Japanese Market Size and Growth

12.2.5 Rest of World Market Size and Growth

12.3 Competitive Analysis

12.3.1 Leading Drugs

12.3.2 Leading Companies

13 Carbapenems

13.1 Overview of Class

13.1.1 Mechanism of Action

13.1.2 Disease Conditions Treated

13.1.3 Adverse Event Profile

13.2 Global Market Analysis

13.2.1 Total World Market Size and Growth

13.2.2 U.S. Market Size and Growth

13.2.3 Western European Market Size and Growth

13.2.4 Japanese Market Size and Growth

13.2.5 Rest of World Market Size and Growth

13.3 Competitive Analysis

13.3.1 Leading Drugs

13.3.2 Leading Companies

14 Oxazolidinones

14.1 Overview of Class

14.1.1 Mechanism of Action

14.1.2 Disease Conditions Treated

14.1.3 Adverse Event Profile

14.2 Global Market Analysis

14.2.1 Total World Market Size and Growth

14.2.2 U.S. Market Size and Growth

14.2.3 Western European Market Size and Growth

14.2.4 Japanese Market Size and Growth

14.2.5 Rest of World Market Size and Growth

14.3 Competitive Analysis

14.3.1 Leading Drugs

14.3.2 Leading Companies

15 Streptogramins

15.1 Overview of Class

15.1.1 Mechanism of Action

15.1.2 Disease Conditions Treated

15.1.3 Adverse Event Profile

15.2 Global Market Analysis

15.2.1 Total World Market Size and Growth

15.2.2 U.S. Market Size and Growth

15.2.3 Western European Market Size and Growth

15.2.4 Japanese Market Size and Growth

15.2.5 Rest of World Market Size and Growth

15.3 Competitive Analysis

15.3.1 Leading Drugs

15.3.2 Leading Companies

16 Other: Rifampin, Clindamycin, Etc.

16.1 Overview of Other Antibiotics

16.1.1 Rifampin

16.1.2 Clindamycin

16.2 Global Market Analysis

16.2.1 Total World Market Size and Growth

16.2.2 U.S. Market Size and Growth

16.2.3 Western European Market Size and Growth

16.2.4 Japanese Market Size and Growth

16.2.5 Rest of World Market Size and Growth

16.3 Competitor Analysis

16.3.1 Leading Drugs

16.3.2 Leading Competitors

17 Overall Market Summary

17.1 Total World Market Projection

17.2 World Market Projections by Antibiotic Class

17.3 World Market Projections by Geographic Region

18 Research Activities

18.1 Peptide Antibiotics

18.2 Bacteriophages

18.3 Iron Absorption Mimicry

19 Company Briefs

19.1 Advancis Pharmaceutical Corp.

19.2 Alcon Laboratories, Inc.

19.3 Cubist Pharmaceuticals, Inc.

19.4 Bayer Corp

19.5 Kyorin Pharmaceutical Co., Ltd

19.6 Daiichi Pharmaceutical Co., Ltd

19.7 Eli Lilly and Co.

19.8 LG Life Sciences, Ltd

19.9 Micrologix Biotech Inc

19.10 Novartis AG

19.11 Pfizer Inc.

19.12 Pliva d.d

19.13 Ranbaxy Laboratories Ltd.

19.14 Toyama Chemical Co., Ltd

19.15 Wyeth

List of Tables

Table 4-1 World Market Size and Growth for Sulphonamides by Drug 2002, 2008

Table 4-2 World Market Size and Growth for Sulphonamides by Geographic Region 2002, 2008

Table 4-3 U.S. Market Size for Sulphonamides by Drug 2002, 2008

Table 4-4 Western European Market Size for Sulphonamides by Drug 2002, 2008

Table 4-5 Japanese Market Size for Sulphonamides by Drug 2002, 2008

Table 4-6 Rest of World Market Size for Sulphonamides by Drug 2002, 2008

Table 4-7 Top-Selling Sulphonamides

Table 4-8 Competitor Revenues and World Market Shares for Sulphonamides 2002

Table 5-1 World Market Size and Growth for Penicillins by Drug 2002, 2008

Table 5-2 World Market Size and Growth for Penicillins by Geographic Region 2002, 2008

Table 5-3 U.S. Market Size for Penicillins by Drug 2002, 2008

Table 5-4 Western European Market Size for Penicillins by Drug 2002, 2008

Table 5-5 Japanese Market Size for Penicillins by Drug 2002, 2008

Table 5-6 Rest of World Market Size for Penicillins by Drug 2002, 2008

Table 5-7 Top-Selling Penicillins

Table 5-8 Competitor Revenues and World Market Shares for Penicillins 2002

Table 6-1 World Market Size and Growth for Tetracyclines by Drug 2002, 2008

Table 6-2 World Market Size and Growth for Tetracyclines by Geographic Region 2002, 2008

Table 6-3 U.S. Market Size for Tetracyclines by Drug 2002, 2008

Table 6-4 Western European Market Size for Tetracyclines by Drug 2002, 2008

Table 6-5 Japanese Market Size for Tetracyclines by Drug 2002, 2008

Table 6-6 Rest of World Market Size for Tetracyclines by Drug 2002, 2008

Table 6-7 Top-Selling Tetracyclines

Table 6-8 Competitor Revenues and World Market Shares for Tetracyclines 2002

Table 7-1 World Market Size and Growth for Cephalosporins by Drug 2002, 2008

Table 7-2 World Market Size and Growth for Cephalosporins by Geographic Region 2002, 2008

Table 7-3 U.S. Market Size for Cephalosporins by Drug 2002, 2008

Table 7-4 Western European Market Size for Cephalosporins by Drug 2002, 2008

Table 7-5 Japanese Market Size for Cephalosporins by Drug 2002, 2008

Table 7-6 Rest of World Market Size for Cephalosporins by Drug 2002, 2008

Table 7-7 Top-Selling Cephalosporins

Table 7-8 Competitor Revenues and World Market Shares for Cephalosporins 2002

Table 8-1 World Market Size and Growth for Cephems by Drug 2002, 2008

Table 8-2 World Market Size and Growth for Cephems by Geographic Region 2002, 2008

Table 8-3 U.S. Market Size for Cephems by Drug 2002, 2008

Table 8-4 Western European Market Size for Cephems by Drug 2002, 2008

Table 8-5 Japanese Market Size for Cephems by Drug 2002, 2008

Table 8-6 Rest of World Market Size for Cephems by Drug 2002, 2008

Table 8-7 Top-Selling Cephems

Table 8-8 Competitor Revenues and World Market Shares for Cephems 2002

Table 9-1 World Market Size and Growth for Aminoglycosides by Drug 2002, 2008

Table 9-2 World Market Size and Growth for Aminoglycosides by Geographic Region 2002, 2008

Table 9-3 U.S. Market Size for Aminoglycosides by Drug 2002, 2008

Table 9-4 Western European Market Size for Aminoglycosides by Drug 2002, 2008

Table 9-5 Japanese Market Size for Aminoglycosides by Drug 2002, 2008

Table 9-6 Rest of World Market Size for Aminoglycosides by Drug 2002, 2008

Table 9-7 Top-Selling Aminoglycosides

Table 9-8 Competitor Revenues and World Market Shares for Aminoglycosides 2002

Table 10-1 World Market Size and Growth for Macrolides by Drug 2002, 2008

Table 10-2 World Market Size and Growth for Macrolides by Geographic Region 2002, 2008

Table 10-3 U.S. Market Size for Macrolides by Drug 2002, 2008

Table 10-4 Western European Market Size for Macrolides by Drug 2002, 2008

Table 10-5 Japanese Market Size for Macrolides by Drug 2002, 2008

Table 10-6 Rest of World Market Size for Macrolides by Drug 2002, 2008

Table 10-7 Top-Selling Macrolides

Table 10-8 Competitor Revenues and World Market Shares for Macrolides 2002

Table 11-1 World Market Size and Growth for Glycopeptides by Drug 2002, 2008

Table 11-2 World Market Size and Growth for Glycopeptides by Geographic Region 2002, 2008

Table 11-3 U.S. Market Size for Glycopeptides by Drug 2002, 2008

Table 11-4 Western European Market Size for Glycopeptides by Drug 2002, 2008

Table 11-5 Japanese Market Size for Glycopeptides by Drug 2002, 2008

Table 11-6 Rest of World Market Size for Glycopeptides by Drug 2002, 2008

Table 11-7 Top-Selling Glycopeptides

Table 11-8 Competitor Revenues and World Market Shares for Glycopeptides 2002

Table 12-1 World Market Size and Growth for Quinolones by Drug 2002, 2008

Table 12-2 World Market Size and Growth for Quinolones by Geographic Region 2002, 2008

Table 12-3 U.S. Market Size for Quinolones by Drug 2002, 2008

Table 12-4 Western European Market Size for Quinolones by Drug 2002, 2008

Table 12-5 Japanese Market Size for Quinolones by Drug 2002, 2008

Table 12-6 Rest of World Market Size for Quinolones by Drug 2002, 2008

Table 12-7 Top-Selling Quinolones

Table 12-8 Competitor Revenues and World Market Shares for Quinolones 2002

Table 13-1 World Market Size and Growth for Carbapenems by Drug 2002, 2008

Table 13-2 World Market Size and Growth for Carbapenems by Geographic Region 2002, 2008

Table 13-3 U.S. Market Size for Carbapenems by Drug 2002, 2008

Table 13-4 Western European Market Size for Carbapenems by Drug 2002, 2008

Table 13-5 Japanese Market Size for Carbapenems by Drug 2002, 2008

Table 13-6 Rest of World Market Size for Carbapenems by Drug 2002, 2008

Table 13-7 Top-Selling Carbapenems

Table 13-8 Competitor Revenues and World Market Shares for Carbapenems 2002

Table 14-1 World Market Size and Growth for Oxazolidinones by Drug 2002, 2008

Table 14-2 World Market Size and Growth for Oxazolidinones by Geographic Region 2002, 2008

Table 14-3 U.S. Market Size for Oxazolidinones by Drug 2002, 2008

Table 14-4 Western European Market Size for Oxazolidinones by Drug 2002, 2008

Table 14-5 Japanese Market Size for Oxazolidinones by Drug 2002, 2008

Table 14-6 Rest of World Market Size for Oxazolidinones by Drug 2002, 2008

Table 15-1 World Market Size and Growth for Streptogramins by Drug 2002, 2008

Table 15-2 World Market Size and Growth for Streptogramins by Geographic Region 2002, 2008

Table 15-3 U.S. Market Size for Streptogramins by Drug 2002, 2008

Table 15-4 Western European Market Size for Streptogramins by Drug 2002, 2008

Table 15-5 Japanese Market Size for Streptogramins by Drug 2002, 2008

Table 15-6 Rest of World Market Size for Streptogramins by Drug 2002, 2008

Table 16-1 World Market Size and Growth for Rifampin, Cleocin, and Others 2002, 2008

Table 16-2 World Market Size and Growth for Rifampin, Cleocin, and Others by Geographic Region 2002, 2008

Table 16-3 U.S. Market Size for Rifampin, Cleocin, and Others 2002, 2008

Table 16-4 Western European Market Size for Rifampin, Cleocin, and Others 2002, 2008

Table 16-5 Japanese Market Size for Rifampin, Cleocin, and Others 2002, 2008

Table 16-6 Rest of World Market Size for Rifampin, Cleocin, and Others 2002, 2008

Table 16-7 Other Top-Selling Antibiotics

Table 17-1 World Market Size for Antibiotics by Drug Class 2002, 2008

Table 17-2 World Market Size for Antibiotics by Geographic Region 2002, 2008

List of Figures

Figure 4-1 World Market Size for Sulphonamides by Drug 2002, 2008

Figure 4-2 World Market Size for Sulphonamides by Geographic Region 2002, 2008

Figure 4-3 U.S. Market Size for Sulphonamides by Drug 2002, 2008

Figure 4-4 Western European Market Size for Sulphonamides by Drug 2002, 2008

Figure 4-5 Japanese Market Size for Sulphonamides by Drug 2002, 2008

Figure 4-6 Rest of World Market Size for Sulphonamides by Drug 2002, 2008

Figure 4-7 Competitor World Market Shares for Sulphonamides 2002

Figure 5-1 World Market Size for Penicillins by Drug 2002, 2008

Figure 5-2 World Market Size for Penicillins by Geographic Region 2002, 2008

Figure 5-3 U.S. Market Size for Penicillins by Drug 2002, 2008

Figure 5-4 Western European Market Size for Penicillins by Drug 2002, 2008

Figure 5-5 Japanese Market Size for Penicillins by Drug 2002, 2008

Figure 5-6 Rest of World Market Size for Penicillins by Drug 2002, 2008

Figure 5-7 Competitor World Market Shares for Penicillins 2002

Figure 6-1 World Market Size for Tetracyclines by Drug 2002, 2008

Figure 6-2 World Market Size for Tetracyclines by Geographic Region 2002, 2008

Figure 6-3 U.S. Market Size for Tetracyclines by Drug 2002, 2008

Figure 6-4 Western European Market Size for Tetracyclines by Drug 2002, 2008

Figure 6-5 Japanese Market Size for Tetracyclines by Drug 2002, 2008

Figure 6-6 Rest of World Market Size for Tetracyclines by Drug 2002, 2008

Figure 6-7 Competitor World Market Shares for Tetracyclines 2002

Figure 7-1 World Market Size for Cephalosporins by Drug 2002, 2008

Figure 7-2 World Market Size for Cephalosporins by Geographic Region 2002, 2008

Figure 7-3 U.S. Market Size for Cephalosporins by Drug 2002, 2008

Figure 7-4 Western European Market Size for Cephalosporins by Drug 2002, 2008

Figure 7-5 Japanese Market Size for Cephalosporins by Drug 2002, 2008

Figure 7-6 Rest of World Market Size for Cephalosporins by Drug 2002, 2008

Figure 7-7 Competitor World Market Shares for Cephalosporins 2002

Figure 8-1 World Market Size for Cephems by Drug 2002, 2008

Figure 8-2 World Market Size for Cephems by Geographic Region 2002, 2008

Figure 8-3 U.S. Market Size for Cephems by Drug 2002, 2008

Figure 8-4 Western European Market Size for Cephems by Drug 2002, 2008

Figure 8-5 Japanese Market Size for Cephems by Drug 2002, 2008

Figure 8-6 Rest of World Market Size for Cephems by Drug 2002, 2008

Figure 8-7 Competitor World Market Shares for Cephems 2002

Figure 9-1 World Market Size for Aminoglycosides by Drug 2002, 2008

Figure 9-2 World Market Size for Aminoglycosides by Geographic Region 2002, 2008

Figure 9-3 U.S. Market Size for Aminoglycosides by Drug 2002, 2008

Figure 9-4 Western European Market Size for Aminoglycosides by Drug 2002, 2008

Figure 9-5 Japanese Market Size for Aminoglycosides by Drug 2002, 2008

Figure 9-6 Rest of World Market Size for Aminoglycosides by Drug 2002, 2008

Figure 9-7 Competitor World Market Shares for Aminoglycosides 2002

Figure 10-1 World Market Size for Macrolides by Drug 2002, 2008

Figure 10-2 World Market Size for Macrolides by Geographic Region 2002, 2008

Figure 10-3 U.S. Market Size for Macrolides by Drug 2002, 2008

Figure 10-4 Western European Market Size for Macrolides by Drug 2002, 2008

Figure 10-5 Japanese Market Size for Macrolides by Drug 2002, 2008

Figure 10-6 Rest of World Market Size for Macrolides by Drug 2002, 2008

Figure 10-7 Competitor World Market Shares for Macrolides 2002

Figure 11-1 World Market Size for Glycopeptides by Drug 2002, 2008

Figure 11-2 World Market Size for Glycopeptides by Geographic Region 2002, 2008

Figure 11-3 U.S. Market Size for Glycopeptides by Drug 2002, 2008

Figure 11-4 Western European Market Size for Glycopeptides by Drug 2002, 2008

Figure 11-5 Japanese Market Size for Glycopeptides by Drug 2002, 2008

Figure 11-6 Rest of World Market Size for Glycopeptides by Drug 2002, 2008

Figure 11-7 Competitor World Market Shares for Glycopeptides 2002

Figure 12-1 World Market Size for Quinolones by Drug 2002, 2008

Figure 12-2 World Market Size for Quinolones by Geographic Region 2002, 2008

Figure 12-3 U.S. Market Size for Quinolones by Drug 2002, 2008

Figure 12-4 Western European Market Size for Quinolones by Drug 2002, 2008

Figure 12-5 Japanese Market Size for Quinolones by Drug 2002, 2008

Figure 12-6 Rest of World Market Size for Quinolones by Drug 2002, 2008

Figure 12-7 Competitor World Market Shares for Quinolones 2002

Figure 13-1 World Market Size for Carbapenems by Drug 2002, 2008

Figure 13-2 World Market Size for Carbapenems by Geographic Region 2002, 2008

Figure 13-3 U.S. Market Size for Carbapenems by Drug 2002, 2008

Figure 13-4 Western European Market Size for Carbapenems by Drug 2002, 2008

Figure 13-5 Japanese Market Size for Carbapenems by Drug 2002, 2008

Figure 13-6 Rest of World Market Size for Carbapenems by Drug 2002, 2008

Figure 13-7 Competitor World Market Shares for Carbapenems 2002

Figure 14-1 World Market Size for Oxazolidinones by Drug 2002, 2008

Figure 14-2 World Market Size for Oxazolidinones by Geographic Region 2002, 2008

Figure 14-3 U.S. Market Size for Oxazolidinones by Drug 2002, 2008

Figure 14-4 Western European Market Size for Oxazolidinones by Drug 2002, 2008

Figure 14-5 Japanese Market Size for Oxazolidinones by Drug 2002, 2008

Figure 14-6 Rest of World Market Size for Oxazolidinones by Drug 2002, 2008

Figure 15-1 World Market Size for Streptogramins by Drug 2002, 2008

Figure 15-2 World Market Size for Streptogramins by Geographic Region 2002, 2008

Figure 15-3 U.S. Market Size for Streptogramins by Drug 2002, 2008

Figure 15-4 Western European Market Size for Streptogramins by Drug 2002, 2008

Figure 15-5 Japanese Market Size for Streptogramins by Drug 2002, 2008

Figure 15-6 Rest of World Market Size for Streptogramins by Drug 2002, 2008

Figure 16-1 World Market Size for Rifampin, Cleocin, and Others 2002, 2008

Figure 16-2 World Market Size for Rifampin, Cleocin, and Others by Geographic Region 2002, 2008

Figure 16-3 U.S. Market Size for Rifampin, Cleocin, and Others 2002, 2008

Figure 16-4 Western European Market Size for Rifampin, Cleocin, and Others 2002, 2008

Figure 16-5 Japanese Market Size for Rifampin, Cleocin, and Others 2002, 2008

Figure 16-6 Rest of World Market Size for Rifampin, Cleocin, and Others 2002, 2008

Figure 17-1 World Market Size for Antibiotics by Drug Class 2002, 2008

Figure 17-2 World Market Size for Antibiotics by Geographic Region 2002, 2008

関連商品

処方薬関連調査レポート

オピオイドの処方にみられる傾向 - 効能面の優位性で画期的な疼痛管理の主力薬であり続けるオピオイド

Prescribing Trends in Opioids - Driven by Efficacy Advantages, Opioids to Remain the Mainstay of Breakthrough Pain Management

価格: ￥281,995 (税抜) より

出版日: 2012年05月

抗高血圧薬市場（〜2017年）：ブロックバスター薬（Diovan、Micardis、Avapro、Atacandなど）の特許失効が目減りを加速

Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion

価格: ￥281,995 (税抜) より

出版日: 2012年03月

世界の皮膚科処方薬市場：第8版（抗ニキビ、アンチエイジング、皮膚炎、抜け毛、乾癬、皮膚癌、肝斑、および脂漏症の治療）

World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)

価格: ￥321,877 (税抜) より

出版日: 2012年03月

無料メールサービス

各カテゴリの最新刊情報やキャンペーン情報をメールにてご案内するサービスです。